Gilead Sciences Analysis: $139B Raised
What is Gilead Sciences?
Global biopharma leader in HIV, liver disease, cancer & inflammation therapies
Employees
11-50
Founded
1987
Valuation
$139.34 billion
HQ Full Address
Melbourne, Victoria, Australia
Revenue Growth Rate
-1%
Product Features & Capabilities
- Therapies for HIV and viral hepatitis
- Oncology treatments
- Inflammation-focused drugs
- Patient safety programs
- Medication access initiatives
- ESG and health equity programs
Investment Focus
Gilead Sciences primarily focuses on the following therapeutic areas: virology, oncology, and inflammation. They are involved in the development of innovative medicines targeting diseases such as HIV, hepatitis, and various cancers.
Other Considerations
Serves 25+ medicines globally; 52 clinical programs across therapeutic areas; #1 U.S. funder of HIV programs; $32 billion in planned U.S. investments; Active in global health equity and access initiatives; Recognized for patient safety and medication access programs
Awards Recognition
Gilead Sciences has received several awards and recognitions in the biotech field, including: 1. **2021 Facility of the Year Awards** - Special Recognition Award for Operational Agility due to COVID-19 impact. 2. **Best Diversity, Equity & Inclusion (DE&I) Prize** at Corporate Secretary and IR Magazine's ESG Integration Awards. 3. **Top 100 Most JUST Companies** by JUST Capital and CNBC, where Gilead ranked fifth in the Pharmaceuticals and Biotech industry. 4. **2023 Global OPEX Award** for Best Strategic Business Transformation at a global operational excellence conference. 5. Recognition by the **Dow Jones Sustainability Index** for its unique approach to Environmental, Social, and Governance (ESG) practices.
Key Innovations
- Sovaldi (sofosbuvir) - Approved in 2013 as a treatment for hepatitis C, recognized for its effectiveness.
- Harvoni (ledipasvir/sofosbuvir) - A combination therapy for hepatitis C that cures the disease in 94% to 99% of cases for genotype 1.
- Truvada (emtricitabine and tenofovir disoproxil fumarate) - Initially approved for treating HIV, later recognized for its use in pre-exposure prophylaxis (PrEP) to prevent HIV infection.
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) - A newer HIV treatment noted for its high expenditure and significant price increases.
- Remdesivir (Veklury) - Developed for the treatment of COVID-19, it received emergency use authorization and later full approval for hospitalized patients. Gilead is also focused on expanding its portfolio through internal research and development, particularly in virology, oncology, and inflammation, aiming to deliver over 10 transformative therapies by 2030.
Latest Funding Round
Gilead Sciences recently announced a funding initiative that includes a total of $12.6 million in grant funding to 19 organizations aimed at improving HIV prevention, anti-stigma, and health equity efforts for Black cisgender and transgender women and girls in the United States. This funding was part of their initiative announced in February 2024. Additionally, Gilead's COMPASS Initiative awarded $3 million in funding to 34 organizations to address the HIV epidemic in the southern United States, which was reported on June 26, 2024.
Regulatory Approvals
- Lenacapavir - The U.S. FDA accepted Gilead's New Drug Application for Lenacapavir, a twice-yearly injectable for HIV prevention, under priority review. The European Medicines Agency (EMA) has also validated Gilead's marketing authorization application for this drug.
- Seladelpar - Gilead's Seladelpar was granted conditional marketing authorization by the EMA for the treatment of primary biliary cholangitis, a rare liver disease.
- Trodelvy - Gilead's drug Trodelvy has been approved for treating patients with HR-positive, HER2-negative breast cancer.
Partnerships
- Genesis Therapeutics - Gilead entered a strategic collaboration with Genesis Therapeutics to discover and develop novel small molecule therapies using AI-driven drug discovery platforms.
- Assembly Biosciences - In October 2023, Gilead and Assembly Biosciences formed a 12-year partnership aimed at advancing the research and development of novel antiviral therapies.
- Terray Therapeutics - Gilead announced a multi-target research collaboration with Terray Therapeutics to discover and develop novel small molecule therapies, which was revealed in December 2024.
- Arcus Biosciences - Gilead expanded its partnership with Arcus Biosciences to include research programs in inflammation, building on their previous collaboration focused on oncology.
- Marengo Therapeutics - Gilead collaborated with Marengo Therapeutics to evaluate Invikafusp alfa and Trodelvy in clinical studies for metastatic breast cancers.
- Aelix Therapeutics - Gilead has been working with Aelix since 2018 on a clinical research collaboration agreement to investigate an investigational HIV vaccine.
Find more companies like Gilead Sciences
Financial Overview
$139BTotal Raised
Gilead Sciences recently announced a funding initiative that includes a total of $12.6 million in grant funding to 19 organizations aimed at improving HIV prevention, anti-stigma, and health equity efforts for Black cisgender and transgender women and girls in the United States. This funding was part of their initiative announced in February 2024. Additionally, Gilead's COMPASS Initiative awarded $3 million in funding to 34 organizations to address the HIV epidemic in the southern United States, which was reported on June 26, 2024.
